To differentiate MMP-expressing tumor cells from resident brain cells and activated microglia/macrophages, we assessed MT-MMP immunoreactivity in IDH1-mutated gliomas (four AII, five AIII, and four OII), because tumor cells bearing this mutation could be clearly identified using a specific IDH1 R132H antibody. Here, IDH1 is linked to central nervous system cancer.